Related references
Note: Only part of the references are listed.Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center
Evripidis Kaltsonoudis et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)
Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?
Fabrizio Cantini et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study
G. Girolomoni et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
ABP 501 for the treatment of rheumatoid arthritis
Eleftherios Pelechas et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2018)
Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4 Six-Month Results From a Controlled Cohort Study
Lieke Tweehuysen et al.
ARTHRITIS & RHEUMATOLOGY (2018)
The American College of Rheumatology White Paper on Biosimilars: It Isn't All White-There Is Some Gray and Black
Roy Fleischmann
ARTHRITIS & RHEUMATOLOGY (2018)
Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases
Jonathan Kay et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy
Paul Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis
Paul Emery et al.
RHEUMATOLOGY (2017)
Patient and Healthcare Professionals Preference for Brenzys vs. Enbrel Autoinjector for Rheumatoid Arthritis: A Randomized Crossover Simulated-Use Study
Marc Egeth et al.
ADVANCES IN THERAPY (2017)
Confirmation on the immunogenicity assay used in the SB4 phase III study: response to the comments by Meacci et al
Paul Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: response to letter by Scheinberg and Azevedo
Paul Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Difference between Enbrel and Benepali treatment groups in hepatobiliary disorders'
Morton Scheinberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Anti Etanercept and anti SB4 antibodies detection: impact of the assay method
Francesca Meacci et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
'Lower anti-drug antibodies with etanercept biosimilar: can Ctrough explain the differences?'
Chirag A. Shah
ANNALS OF THE RHEUMATIC DISEASES (2016)
The changing landscape of biosimilars in rheumatology
Thomas Doerner et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
A randomized phase I pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects
Yoon Jung Lee et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept
Ick Hyun Cho et al.
MABS (2016)
Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe
Kunal Thakur et al.
RHEUMATOLOGY AND THERAPY (2016)
Costs of drugs for treatment of rheumatic diseases
Rene Westhovens et al.
RMD OPEN (2016)
Biosimilar monoclonal antibodies: the scientific basis for extrapolation
Huub Schellekens et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Biosimilars for the management of rheumatoid arthritis: economic considerations
Laszlo Gulacsi et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2015)
The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
Bella Ungar et al.
GUT (2014)
Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
Niels Vande Casteele et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation
Pauline A. van Schouwenburg et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease
Casper Steenholdt et al.
INFLAMMATORY BOWEL DISEASES (2012)
Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapy
S. Danese et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Immunogenicity of anti-tumor necrosis factor antibodies - toward improved methods of anti-antibody measurement
Lucien Aarden et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
Share Paper
